GI side effects are common on GLP-1 drugs and mostly happen while the dose is being raised. On the Wegovy label, 73% of adults on the injection had one versus 47% on placebo; nausea hit 44% versus 16%. Most cases are mild to moderate and fade with time, and in STEP 1 only 4.5% stopped treatment because of them.[7][1]
Almost everyone who starts a GLP-1 medication wants to know the same two things: how likely am I to feel sick, and how long will it last? The answer is well-documented because every pivotal trial reported its adverse-event tables in detail. The short version: gastrointestinal effects are common, usually mild to moderate, concentrated in the early dose-escalation weeks, and they fade for most people. Here is what the trials actually show.
Nausea is the headline — and it's common
In STEP 1, with once-weekly semaglutide 2.4 mg, nausea and diarrhea were the most common adverse events, typically transient and mild to moderate, and they subsided with time.[1] Across the Wegovy weight-loss trials pooled on the label, 73% of people on the injection versus 47% on placebo reported a GI reaction: nausea 44% vs 16%, diarrhea 30% vs 16%, vomiting 25% vs 6%, and constipation 24% vs 11%. Severe GI reactions were reported in 4.1% vs 0.9%.[7] In STEP 2, in people with type 2 diabetes, the pattern was the same: GI adverse events, mostly mild to moderate, were reported by 63.5% on semaglutide 2.4 mg versus 34.3% on placebo.[2] The consistent finding across the program is that GI symptoms are the defining tolerability issue of the class, not a rare surprise.
The timeline: front-loaded, then it settles
The key practical fact is when these symptoms happen. GLP-1 doses are escalated stepwise specifically to limit nausea, and the Wegovy label states that GI reactions “were most frequently reported during dosage escalation.”[7] In STEP 8, which compared semaglutide with daily liraglutide over 68 weeks, GI adverse events were reported by 84.1% on semaglutide and 82.7% on liraglutide, yet 13.5% stopped semaglutide for any reason versus 27.6% for liraglutide.[3] The lived pattern for most people: roughest in the first weeks after starting or stepping up, easier by the time they reach the maintenance dose.
Tirzepatide looks similar — same class, same curve
The dual GIP/GLP-1 agonist tirzepatide carries a comparable profile. In SURMOUNT-1, the most common adverse events were gastrointestinal — nausea, diarrhea, constipation, and vomiting — mostly mild to moderate and arising primarily during dose escalation; adverse events caused discontinuation in 4.3%, 7.1% and 6.2% of the 5, 10 and 15 mg groups against 2.6% on placebo.[4] In the head-to-head SURPASS-2 trial in diabetes, GI rates for tirzepatide were in the same range as semaglutide 1 mg: nausea 17% to 22% vs 18%, diarrhea 13% to 16% vs 12%, and vomiting 6% to 10% vs 8%.[5] The takeaway: adding the GIP pathway did not fundamentally change the kind or timing of GI side effects.
How often do people quit because of it?
Discontinuation specifically for GI reasons is the number that matters for “will I be able to stay on it.” Across the trials it is a minority. In STEP 1, 59 of about 1,300 people on semaglutide (4.5%) stopped treatment because of GI events, versus 0.8% on placebo.[1] In SUSTAIN 7, comparing semaglutide with dulaglutide in type 2 diabetes, GI disorders were the most frequently reported adverse event (43% at 0.5 mg semaglutide and 44% at 1.0 mg, against 33% and 48% on the two dulaglutide doses) and the most common reason for stopping treatment, while 72 of the 1,201 participants (6%) withdrew from the trial for any reason.[6] So while feeling some nausea is common, having to stop the drug because of it is considerably less so.
What this means in practice
Three things follow from the data. First, expect some GI symptoms, especially early — they are the rule, not a sign something is wrong. Second, the slow dose-escalation schedule exists precisely to blunt them, which is why skipping ahead tends to backfire — the dose ladder is the first lever in a practical guide to managing GLP-1 nausea, constipation and burping. Third, most people's symptoms ease as they reach a steady dose, and outright discontinuation for GI reasons is the exception. None of this is medical advice for your situation — severe or persistent vomiting, dehydration, or severe abdominal pain always warrant a call to a clinician.
The honest bottom line
GLP-1 GI side effects are common, predictable, and time-limited for most people: nausea leads, the symptoms cluster in the early escalation weeks, and they fade as the dose stabilizes. The trials are remarkably consistent on this across semaglutide and tirzepatide. The realistic expectation is a rocky few weeks, not a permanent state.